All In Biotech

Drug Trial Radar · NCT07926594

Effectiveness Study of TRYPTYR in Dry Eye Disease

A Phase IV Multicenter Evaluation of the Effectiveness of TRYPTYR in Improving Patient Signs and Symptoms With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Scott & Christie and Associates, PCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sengi
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, prospective, open-label, single-arm effectiveness of acoltremon 0.003% in improving patient signs and symptoms with dry eye disease. Subjects will be assessed at baseline, and after 7, 14, and 28 days of treatment. Clinical evaluations will include administration of the Eye Dryness Score Visual Analog Scale (EDS-VAS), measurement of visual acuity at distance, corneal fluorescein staining, conjunctival lissamine green staining, and Pain Numerical Rating Scale assessment.

Conditions

  • Dry Eye Disease

Interventions

  • Acoltremon 0.003% (TRYPTYR)Drug

    1 drop per eye, twice daily (morning and evening approximately 12 hours apart), at consistent times.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from Baseline in Eye Dryness Score Visual Analog Scale (EDS-VAS).Time frame: 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Doctor My Eyes

    Scottsdale, Arizona · Recruiting

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.